(Reuters) – Immunomedics, Inc said on Friday its treatment, Trodelvy, helped partially reduce tumor size in an early-stage study testing it in brain cancer patients.
On Sunday, Gilead Sciences inc said it would buy Immunomedics for $21 billion.
(Reporting by Manas Mishra in Bengaluru)
